Filgotinib meets in Phase II for psoriatic arthritis

Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said in May that once-daily 200 mg oral

Read the full 177 word article

User Sign In